Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

New phase II study evaluates encaleret for autosomal dominant hypocalcemia type 1

Sep. 22, 2020

Bristol-Myers Squibb presents new MGAT2 inhibitors

Sep. 22, 2020

Discovery of novel potent and orally bioavailable SGLT1 and SGLT2 dual inhibitors

Sep. 21, 2020

First-in-human study of progerinin

Sep. 21, 2020

Enrollment ongoing in phase I study of INV-101

Sep. 17, 2020

CAEL-101 enters phase III program for AL amyloidosis

Sep. 15, 2020

Phase IIb topline results for Diamyd in type 1 diabetes

Sep. 15, 2020

Galapagos discloses PASK inhibitors

Sep. 14, 2020

Cyclo Therapeutics reports further data from phase I/II study of Trappsol Cyclo in NPC1

Sep. 10, 2020

ProTrans-2 study meets primary endpoint

Sep. 10, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Regulatory actions for May 5, 2026
BioWorld
Regulatory snapshots for biopharma and med tech, including global submissions and approvals, and other regulatory decisions and designations: Adma, Applied...